Regentys Overview

  • Founded

  • 2013

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 4

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $15M

Regentys General Information

Description

Manufacturer of medical devices created to treat gastrointestinal (GI) disorders. The company manufactures a porcine-derived biological material which acts as a catalyst to stimulate the body to grow new, healthy tissue in place of diseased or damaged tissue and it mainly focuses on tissue-engineered treatment for Inflammatory Bowel Disease (IBD), enabling patients to recover gastrointestinal (GI) disorders.

Contact Information

Website
www.regentys.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Generex Biotechnology
Primary Office
  • 6135 Northwest 167th Street
  • Suite E15
  • Hialeah, FL 33015
  • United States
+1 (844) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regentys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 07-Jan-2019 $15M 00.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 07-Nov-2016 00.000 00.00 Completed Generating Revenue
1. Accelerator/Incubator 31-Oct-2014 $250K $250K 000 Completed Generating Revenue
To view Regentys’s complete valuation and funding history, request access »

Regentys Patents

  • 24

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Regentys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017313207-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Inactive 19-Aug-2016 00000000000
CA-3034251-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Pending 19-Aug-2016 00000000000
EP-3500193-A4 Extracellular matrix for tissue reconstruction of mucosal tissue Pending 19-Aug-2016 00000000000 0
EP-3500193-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Pending 19-Aug-2016 00000000000
US-20190184060-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Inactive 19-Aug-2016 A61L27/3633
To view Regentys’s complete patent history, request access »

Regentys Executive Team (6)

Name Title Board Seat Contact Info
Richard Bulman Jr. Co-Founder & Chief Executive Officer
Christine Sapan Ph.D Co-Founder & Chief Scientific Officer
Steven Wexner Ph.D Chief Medical Officer
Gerard Coombs Co-Founder, Executive Vice President, Operations and Board Member
Marc Ramer Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Regentys Board Members (6)

Name Representing Role Since
Darren Sloniger Self Board Member 000 0000
Hal Wrigley Regentys Board Member 000 0000
Michael Phalen Self Board Member 000 0000
Reginald Hardy Self Board Member 000 0000
Sergio Gonzalez JD Regentys Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Regentys Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regentys Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
43North Accelerator/Incubator Minority 000 0000 000000 0
To view Regentys’s complete investors history, request access »

Ready to get started?

Request a free trial